Nuedexta

Nuedexta is a brand name of dextromethorphan/quinidine, approved by the FDA in the following formulation(s):

NUEDEXTA (dextromethorphan hydrobromide; quinidine sulfate - capsule; oral)

• 
  Manufacturer: AVANIR PHARMS
  
  Approval date: October 29, 2010
  
  Strength(s): 20MG;10MG ^[RLD]

Has a generic version of Nuedexta been approved?

No. There is currently no therapeutically equivalent version of Nuedexta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuedexta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for reducing emotional lability
  Patent 5,206,248
  Issued: April 27, 1993
  Inventor(s): Smith; Richard A.
  This invention discloses that certain types of non-addictive opioid drugs such as dextromethorphan (which is widely used in cough syrups) provide a highly effective means of treating the feelings and symptoms of emotional lability in at least some patients suffering from neurologic impairment, without sedating, tranquilizing, or otherwise significantly interfering with consciousness or alertness in the patient. In several patients tested to date who were suffering from amyotrophic lateral sclerosis (ALS), dextromethorphan, administered orally, was remarkably effective and became quite obvious to the patients even though it was being tested for an entirely different purpose. Its effectiveness is enhanced by co-administration of a second drug such as quinidine which reduces the degradation of dextromethorphan by oxidative enzymes and which therefore increases dextromethorphan concentrations in the blood.
  
  Patent expiration dates:
  
  
  • March 27, 2012
    
    ✓ 
    Patent use: TREATMENT OF PSEUDOBULBAR AFFECT
  
  



• 
  Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
  Patent 7,659,282
  Issued: February 9, 2010
  Inventor(s): Yakatan; Gerald & Berg; James & Pope; Laura E. & Smith; Richard A.
  Assignee(s): Avanir Pharmaceuticals, Inc.
  Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
  
  Patent expiration dates:
  
  
  • August 13, 2026
    
    ✓ 
    Patent use: TREATMENT OF PSEUDOBULBAR AFFECT
  
  



• 
  Dextromethorphan and an oxidase inhibitor for treating intractable conditions
  Patent RE38115
  Issued: May 6, 2003
  Inventor(s): Richard Alan; Smith & Jonathan M.; Licht
  Assignee(s): Center for Neurologic Study
  Methods are disclosed for increasing the effectiveness of dextromethorphan in treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction comprising administering dextromethorphan in combination with a therapeutically effective dosage of a debrisoquin hydroxylase inhibitor. A preferred combination is dextromethorphan and the oxidative inhibitor quinidine.
  
  Patent expiration dates:
  
  
  • January 26, 2016
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 29, 2013 - NEW COMBINATION
  
  

See also...

• Nuedexta Consumer Information (Drugs.com)
• Nuedexta Consumer Information (Wolters Kluwer)
• Nuedexta Consumer Information (Cerner Multum)
• Nuedexta Advanced Consumer Information (Micromedex)
• Dextromethorphan/Quinidine Consumer Information (Wolters Kluwer)
• Dextromethorphan and quinidine Consumer Information (Cerner Multum)
• Dextromethorphan and quinidine Advanced Consumer Information (Micromedex)